Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome
Objective: To investigate the efficacy and safety of decitabine combined with half the amount of CAG and CAG regimen alone. Methods: Comparison the effectiveness, overall survival and incidence of adverse reactions of 42 cases of MDS used decitabine combined with half the amount of CAG regimen (deci...
Main Authors: | Fan Zhenwei, Wang Xuan, Zhao Chunshan, Wang Wei, Yu Tingting |
---|---|
Format: | Article |
Language: | English |
Published: |
EDP Sciences
2017-01-01
|
Series: | BIO Web of Conferences |
Online Access: | http://dx.doi.org/10.1051/bioconf/20170801024 |
Similar Items
-
Next-generation sequencing reveals relapse and leukemia-free survival risks in newly diagnosed acute myeloid leukemia treated with CAG regimen combined with decitabine
by: Sai Huang, et al.
Published: (2024-04-01) -
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
by: Wei Guoqing, et al.
Published: (2011-11-01) -
Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial
by: Yifan Liu, et al.
Published: (2023-11-01) -
Cag type IV secretion system: CagI independent bacterial surface localization of CagA.
by: Navin Kumar, et al.
Published: (2013-01-01) -
Mechanism of regulation of the Helicobacter pylori Cagβ ATPase by CagZ
by: Xiuling Wu, et al.
Published: (2023-01-01)